Latham & Watkins

Testimonials

Collated independently by Legal 500 research team.

• ‘Dynamism, competence and customer focus.’

• ‘Eveline Van Keymeulen is excellent, both for her precise and relevant analyses of developments in the regulatory environment, and for listening and adapting to client needs.’

• ‘Highest level team in life sciences. Expert advice, experience and responsiveness.’

• ‘The team, led by Eveline Van Keymeulen and notably composed of Jeanne Fabre, stands out in particular for its understanding of customer issues, thanks to an analysis and mastery of legal issues without equivalent on the market.’

• ‘The team stands out for its multidisciplinary expertise covering regulatory matters, clinical trials, marketing and compliance. Their advice is always based on in-depth knowledge of the pharmaceutical, biotechnology and medical device sectors, which allows them to provide comprehensive and practical solutions. I see them as leaders in the field thanks to their ability to navigate complex situations on a European scale.’

• ‘Eveline Van Keymeulen particularly stands out for her mastery of EU regulatory law. Her ability to solve complex problems in the life sciences is unrivaled. It is also very proactive, allowing companies to anticipate regulatory challenges.’

• ‘Jeanne Fabre demonstrated excellent business acumen and technical competence. Her knowledge of the dynamics of the healthcare sector, particularly in the regulatory area, makes her a valuable advocate for any company operating in Europe.’

• ‘These lawyers stand out from their peers with their client-centric approach, in-depth industry knowledge and ability to provide practical, actionable advice.’

Key clients

Work highlights

Lawyers

Next Generation Partners

Eveline Van Keymeulen

Latham & Watkins LLP

Eveline Van Keymeulen is a partner in Latham & Watkins' Brussels and Paris offices and Global Vice Chair of Latham & Watkins' Healthcare & Life Sciences Practice. She advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics, and food and beverage sectors on a broad variety of complex European, domestic and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations, and general compliance matters. In addition, Eveline has extensive experience advising on cannabis and hemp-based product regulations. She successfully challenged the legality of French hemp regulations in the first landmark case related to cannabidiol (CBD) products before the Court of Justice of the European Union (Case C-663/18, Kanavape). This transaction won the Creating New Standards award at the Financial Times European Innovative Lawyer Awards 2022. Eveline has authored numerous articles and has been a featured speaker on EU regulatory matters at prominent conferences such as the Pharmaceutical Law Academy in Cambridge. She also serves on the editorial board of the European Pharmaceutical Law Review. In addition, Eveline has been quoted in BBC Business Daily, Bloomberg, The Times, Les Echos, and other leading international business journals on life sciences regulatory and policy matters.